Clinical Trials Browser

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT02624128 2023-11-13

V-CHANCE

Phase 2 Unknown

39 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT05260671 2023-10-18

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Phase 2 Recruiting

48 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT01864772 2022-08-19

ELANFIT

Phase 2 Completed

85 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT03887442 2021-01-07

EXTAX

Phase 2 Terminated

17 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT02124707 2020-08-12

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

Phase 2 Completed

14 enrolled 17 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT01488318 2018-01-05

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase 2 Terminated

21 enrolled 8 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT01794845 2017-05-11

Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma

Phase 2 Terminated

5 enrolled 9 charts

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Recurrence

NCT01040832 2017-01-30

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

107 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms, Recurrence

NCT01133665 2014-11-24

Cetuximab and Lenalidomide in Head and Neck

Phase 2 Completed

42 enrolled 42 charts

Carcinoma, Squamous Cell, Recurrence

NCT01427205 2013-04-05

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 2 Withdrawn

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases, Neoplasm Metastasis, Recurrence